An interventional study of Compensatory Cognitive Training for COVID-19 and Holistic Cognitive Education in Post-Acute COVID-19 Syndrome, sponsored by VA Office of Research and Development. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Post-Acute COVID-19 Syndrome by VA Office of Research and Development — 8 open to participants now, 8 under way, none of them phase 3. Post-Acute COVID-19 Syndrome · VA Office of Research and Development.
Among the 11 studies in Post-Acute COVID-19 Syndrome by VA Office of Research and Development, this one is one of 3 that started in 2024, is one of 7 with no phase, and was the 7th registered.
606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →8 of the 11 studies in Post-Acute COVID-19 Syndrome by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 18–80
VA Office of Research and Development · Sites in United States
VA Office of Research and Development · Sites in United States
Ages 18–89
VA Office of Research and Development · Sites in United States
Ages up to 80 · Healthy volunteers
By country, each count listing its studies:
Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 3 started in 2024.
This study's planned enrollment of 70 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 60 across the 8 interventional studies, 200 across the 3 observational. Of the 3 that completed or were terminated, 2 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
VA Office of Research and Development is the lead sponsor of 1,774 studies on the registry; 394 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.
5 of the studies in Post-Acute COVID-19 Syndrome by VA Office of Research and Development that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06142253VA Office of Research and DevelopmentWater-based Activity to Enhance Recovery in Long COVID-19 | 2026-12-31 |
| NCT06291870VA Office of Research and DevelopmentPredictors of Post-COVID-19 Clinical and Cognitive Consequences | 2026-12-31 |
| NCT06086379VA Office of Research and DevelopmentCognitive Rehabilitation Therapy for COVID-19 | 2027-06-30 |
| NCT05373043VA Office of Research and DevelopmentLong-term COVID and Rehabilitation | 2027-10-31 |
| NCT05787379VA Office of Research and DevelopmentCare for Veterans Post-COVID-19 | 2027-11-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 11 studies in Post-Acute COVID-19 Syndrome by VA Office of Research and Development, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Cognitive dysfunction, psychiatric symptoms, functional impairment, and disability following COVID-19 negatively impact Veterans' community functioning and quality of life, contribute to significant human suffering, and are costly to VHA. Rehabilitation is a critical priority for Veterans with long COVID. One promising treatment to improve functioning in Veterans with post-COVID-19 cognitive symptoms is Compensatory Cognitive Training (CCT). Previous studies have found that CCT is feasible, acceptable, and efficacious in Veteran populations with multiple sources of cognitive dysfunction. This randomized controlled trial aims to address important RR\&D priorities by examining feasibility, acceptability, and preliminary efficacy of a COVID-19-specific rehabilitation intervention, CCT for long COVID (CCT-C) compared to a robust control condition. The proposed study has the potential to improve cognitive function, functional independence, and quality of life for Veterans with late or delayed effects of secondary conditions related to COVID-19 infections.
2-8% of the US population report "long COVID" symptoms - including "brain fog," thinking difficulties, memory problems, and psychiatric symptoms such as sleep disturbance, anxiety, and depression. Rates of post-COVID-19 symptoms are nearly double in the Veteran population. These cognitive symptoms contribute to functional impairments, reduced quality of life, poorer self-reported health status, psychological distress, delayed return to work, new onset disability, reduced community integration, and increased healthcare utilization. One promising treatment to improve both everyday functioning and cognition secondary to post-COVID-19 symptoms is Compensatory Cognitive Training (CCT). Previous studies have found that CCT is feasible, acceptable, and efficacious in Veteran populations with multiple sources of cognitive dysfunction. The proposed CDA provides a golden opportunity to evaluate CCT for Veterans with prolonged COVID-19 symptoms (CCT-C), compared with a robust control condition, Holistic Cognitive Education (HCE). The project closely aligns with current RR\&D priorities, by "examining COVID-19-specific rehabilitation interventions and responses to treatment" and by addressing "late or delayed effects of secondary conditions related to COVID-19 infections on impairment and disability." Specific aims are 1) to conduct a pilot randomized controlled trial of remote CCT-C with 70 Veterans (35 CCT-C, 35 HCE) with post-COVID-19 cognitive symptoms to examine feasibility, acceptability, and initial efficacy; 2) to examine the preliminary efficacy of CCT-C in this population on overall functioning, as measured by the World Health Organization's Disability Assessment Schedule (WHODAS 2.0), performance-based measures of functional capacity, and secondary outcomes (cognitive performance, quality of life, self-reported cognitive problems, psychiatric symptoms, sleep disturbance, and engagement in work/community activities); and 3) to explore moderators of outcome (e.g., age, initial COVID-19 severity, baseline cognitive functioning, presence of PTSD/mTBI history; biomarkers related to COVID-19 infection).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10-week Compensatory Cognitive Training Group
Behavioral: Compensatory Cognitive Training for COVID-19
10-week Holistic Cognitive Education Group
Behavioral: Holistic Cognitive Education
CCT-C is a manualized group-based behavioral intervention (10 weeks, 2 hours per week, 20 hours total) designed to improve cognition and everyday functioning in patients with prolonged COVID-19 symptoms
Also known as: CCT-C
HCE provides the same frequency and amount of therapist and other group member contact as CCT-C, but does not provide training in cognitive or lifestyle strategies addressed in CCT-C. The HCE intervention provides information and discussion regarding common causes of and treatments for cognitive impairment.
Also known as: HCE
Change in World Health Organization - Disability Assessment Schedule (WHODAS 2.0)
Change in average total score
Time frame: baseline, 8 weeks
Change in objective cognitive performance z score
Change in composite z score
Time frame: baseline, 8 weeks
Change in functional capacity performance z score
Change in composite z score
Time frame: baseline, 8 weeks
Change in Patient Health Questionnaire 9 (PHQ-9)
Change in total score
Time frame: baseline, 8 weeks
Change in Generalized Anxiety Disorder 7 (GAD-7)
Change in total score
Time frame: baseline, 8 weeks
Change in PTSD Checklist for DSM-5 (PCL-5)
Change in total score
Time frame: baseline, 8 weeks
Change in Cognitive Failures Questionnaire (CFQ)
Change in total score
Time frame: baseline, 8 weeks
Change in Neuro-QOL: Applied Cognition General Concerns
Change in total score
Time frame: baseline, 8 weeks
Change in Neuro-QOL: Applied Cognition Executive Functioning
Change in total score
Time frame: baseline, 8 weeks
Change in Neuro-QOL: Fatigue
Change in total score
Time frame: baseline, 8 weeks
Change in World Health Organization - Quality of Life (WHOQOL-BREF)
Change in total score
Time frame: baseline, 8 weeks
Change in Insomnia Severity Index (ISI)
Change in total score
Time frame: baseline, 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Jun 2027, 35 months after the start.
Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 35 months is above that.
Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →
VA Office of Research and Development →